The prevention of HER-2+ metastasis development using the Triplex vaccine (Nanni et al., 2007) indicated that effective anti-HER-2 vaccines could be included in adjuvant therapy of HER-2+ breast cancer, possibly as a strategy to maintain a long-term antibody response to p185 after cessation of the monoclonal antibody regimens. Here, ERBB2 is linked to breast carcinoma.